When the Gatekeeper Wants More Keys: What Centene’s FWA Reform Proposal Really Means for Providers

By Elena Pak, Credentialing Department, WCH

On February 25, 2026, Centene — the largest Medicaid managed care organization in the United States, holding approximately 17.7% of the national Medicaid managed care market — submitted a formal letter to CMS outlining seven proposed reforms to how MCOs are permitted to fight fraud, waste, and abuse. The framing was unimpeachable: protect taxpayers, stop bad actors, preserve program integrity.

The problem it describes is real. Several of the regulatory frustrations Centene identifies are genuinely legitimate. Which is precisely why providers need to read this proposal carefully — because what is framed as an anti-fraud initiative is also, structurally, an expansion of payer authority over provider payments, audits, and network participation. The two things are not mutually exclusive. They rarely are.

The Seven Reforms: A Closer Read

Centene’s letter asks CMS to: permit proactive payment suspensions without a waiting period for government approval; broaden prepayment review capabilities; standardize program integrity requirements nationally; require data-sharing among MCOs, state agencies, and law enforcement; allow prompt-pay exceptions during active claim investigations; permit statistical sampling and extrapolation for audits; and allow FWA prevention expenses to count in the medical loss ratio (MLR) numerator.

Some of these are straightforward. The push to adopt a national, cross-program taxonomy for FWA — standardized referral thresholds, timeframes, and data formats — addresses a genuine inefficiency: the current patchwork of state-by-state reporting requirements forces fraud investigation teams to devote resources to administrative paperwork instead of pursuing wrongdoers. This reform, if implemented thoughtfully, benefits providers as much as payers.

Mandatory data-sharing between MCOs, state agencies, and law enforcement is similarly defensible in principle. Cross-jurisdictional fraud schemes exploit information siloes, and coordinated intelligence has an obvious role in disrupting them.

The remaining proposals deserve considerably harder scrutiny.

Prepayment Review Without Time Limits: A Cash Flow Event

Centene is asking CMS to empower MCOs to conduct data-driven prepayment reviews without pre-approval requirements or time limits, maintaining oversight — as the letter puts it — “until billing issues are fully resolved.”

For providers, prepayment review is not an abstract inconvenience. It is a cash flow event. When a payer places a practice under prepayment scrutiny, claims stop processing while the investigation proceeds — often for months. Under current federal rules (42 CFR § 455.23), payment suspensions are explicitly intended to be temporary in nature and subject to ongoing review. States must evaluate allegations on a case-by-case basis before acting.

Centene’s proposal would remove those guardrails in favor of MCO discretion, with no specified endpoint and no defined appeals mechanism. Providers facing wrongful suspensions currently have procedural recourse — notice requirements, defined review periods, a documented evidentiary basis for the action. Under the proposed framework, the threshold for initiating review, the standards for conducting it, and the criteria for concluding it would all reside with the payer.

The question providers should be asking is not whether prepayment review is ever appropriate — it clearly is — but who decides when it ends, under what standard, and what recourse exists when the determination is operationally applied before a final fraud finding has been made.

Audit Sampling and Extrapolation: The Multiplier That Changes Everything

This is the highest-stakes item in the letter, and the one that warrants the most careful provider attention.

When a provider is subject to an extrapolated overpayment demand, the individual claims denial amounts are typically modest — but the final recovery figure can reach hundreds of thousands or millions of dollars when an error rate is applied across an entire claims universe. A 20% error rate found in a 50-claim sample, extrapolated across 5,000 claims, produces a recoupment demand that no individual audit finding would have generated. As one recent OIG audit demonstrated, $480,000 in sample overpayments extrapolated to $27 million — a 55x multiplier.

The regulatory irony is significant. According to CMS impact estimates, the agency projected recovering $4.7 billion through RADV extrapolation between 2023 and 2032 — a methodology that a federal district court then vacated in September 2025, ruling that CMS lacked authority to apply extrapolation under the final rule. HHS has appealed, and the underlying audit program continues without extrapolation while litigation proceeds.

Centene is now asking for this same tool to be placed in MCO hands for Medicaid FWA audits, with no indication of what procedural standards would govern its application. Under existing Medicare frameworks, extrapolation is subject to strict prerequisites: a sustained or high level of payment error must be established, and the sampling methodology and extrapolation calculations are themselves appealable. Whether any comparable constraints would apply to Centene’s proposed MCO authority is unaddressed.

CMS has separately announced its intention to audit all approximately 550 eligible Medicare Advantage contracts annually — up from roughly 60 per year — while expanding its medical coding workforce from 40 to approximately 2,000 reviewers. This infrastructure expansion signals where enforcement is heading across programs, not just in Medicare Advantage.

Prompt Pay Exceptions and Network Adequacy Waivers

Centene frames the prompt-pay and network-adequacy items as a conflict between two regulatory obligations: MCOs must fight FWA, but are also required to pay claims within defined timeframes and maintain adequate provider networks. The tension is real. But the practical effect of a prompt-pay exception with no defined outer limit is that any claim flagged for investigation can be delayed indefinitely without financial penalty to the payer.

The definition of “active investigation” matters enormously here — and Centene’s proposal does not define it. Nor does it specify the process by which a provider could contest a determination, request an independent review, or trigger a timeline for resolution. In the absence of those procedural details, the exception functions as a broad delay mechanism rather than a targeted investigative tool.

The network-adequacy waiver raises a parallel concern. When a provider is removed for documented fraud, the obligation to find a replacement is currently incentivized by network-adequacy requirements. Waiving those requirements during the transition removes the structural pressure on an MCO to act quickly — meaning patients in underserved areas may experience access gaps while the payer operates below required ratios without regulatory consequence.

The MLR Item: Small Print, Big Incentive

One proposal in Centene’s letter has received less commentary than it deserves: the request that FWA prevention expenses be counted in the MLR numerator across all government-sponsored health programs.

Under current federal MLR rules, the numerator includes incurred claims, quality improvement expenditures, and a defined category of fraud prevention activities — but only within specific regulatory parameters under 42 CFR § 438.8(e)(4). Centene is asking for this treatment to be broadened and standardized.

The financial logic is straightforward: an MCO whose MLR is already near or above the 85% minimum threshold has limited incentive to invest in expensive anti-fraud infrastructure, because those expenditures currently count as administrative costs — pulling the MLR down and potentially triggering rebate obligations. If FWA prevention expenses move into the numerator, MCOs can invest more aggressively in program integrity without MLR penalty. This could mean better-targeted enforcement — or simply more enforcement at scale.

Notably, Centene is currently operating at a Medicaid MLR of approximately 93%, well above minimum thresholds. The company has significantly more headroom to invest in FWA infrastructure than most. For smaller MCOs operating near the 85% floor, the same regulatory change could function as a competitive disadvantage if the compliance investments it encourages are primarily accessible to large plans with existing infrastructure.

The Broader Enforcement Context

Centene’s letter does not arrive in a vacuum. On February 25, 2026 — the same day the letter was submitted — the Trump administration announced a deferral of $259.5 million in federal Medicaid matching funds to Minnesota, citing $243.8 million in unsupported or potentially fraudulent Medicaid claims and $15.4 million in claims involving individuals lacking satisfactory immigration status. CMS simultaneously imposed a six-month nationwide moratorium on new Medicare enrollment for certain durable medical equipment suppliers and launched the CRUSH initiative — Comprehensive Regulations to Uncover Suspicious Healthcare — seeking public comment on additional anti-fraud rulemaking.

CMS reported suspending $5.7 billion in suspected fraudulent Medicare payments in 2025 and making 372 fraud referrals totaling $3.7 billion to law enforcement. The appetite for enforcement, across the administration and across programs, is operating at a sustained high — and the infrastructure to support it is being scaled accordingly.

What Providers Should Do

Three things are clear from this proposal, regardless of whether CMS adopts it in whole, in part, or not at all.

First, the FWA enforcement environment of 2026 is not a temporary posture. It reflects a sustained policy shift toward utilization control, documentation enforcement, and cost containment. That shift predates Centene’s letter by several years and will outlast any single regulatory decision.

Second, documentation has never been more consequential. Every proposal Centene advances — prepayment review, audit extrapolation, anomaly-based targeting — is operationalized through claims data and medical records. The time to build a defensible documentation posture is before a review begins, not after the letter arrives.

Third, the appeals process matters more than most practices realize. Under existing Medicare frameworks, the sampling methodology and extrapolation calculations used in audits are both subject to appeal, even where the decision to audit is not. Practices that understand audit mechanics before they become audit targets are positioned to push back effectively when the methodology is flawed. Those that don’t are left disputing conclusions rather than the process that generated them.

The problem with FWA enforcement has never been that it exists — it must. The problem is that the audit and payment tools being requested are operationally applied before any fraud determination has been made. The compliance infrastructure being built around these proposals does not discriminate by intent. It discriminates by data pattern — which are, as any provider who has faced a wrongful denial knows, imperfect proxies for actual conduct.

Sources

1. Centene Corporation. FWA Reform Letter to CMS, February 25, 2026. centene.com/why-were-different/healthcare-fraud-waste-abuse-oversight/centene-fwa-reform-letter.html
2. Health Management Associates Information Services. “Medicaid Managed Care Enrollment Update — Q1 2025.” March 2025. healthmanagement.com. (Centene: 17.7% national Medicaid managed care market share.)
3. KFF. “A Look at Medicaid Enrollment and Finances of the Five Largest Medicaid Managed Care Plans.” August 2025. kff.org.
4. Georgetown Center for Children and Families. “Medicaid Managed Care: The Big Five in Q4 2025.” February 20, 2026. ccf.georgetown.edu.
5. Becker’s Payer Issues. “CMS Freezes $260M in Medicaid Funding to Minnesota, Citing Fraud Concerns.” February 25, 2026. beckerspayer.com.
6. Healthcare Finance News. “HHS Defers $259.5 Million in Medicaid Funding to Minnesota.” February 2026. healthcarefinancenews.com. (Exact figure: $259,505,491; $243.8M unsupported/potentially fraudulent; $15.4M immigration-status claims.)
7. Georgetown Center for Children and Families. “CMS Weaponizes Fraud Against Medicaid in Minnesota: Part 2.” March 2, 2026. ccf.georgetown.edu.
8. CMS. CRUSH Initiative. February 25, 2026. cms.gov.
9. Morgan Lewis. “CMS’s Final RADV Rule Announces No Extrapolation Methodology, No FFS Adjuster.” February 2023. morganlewis.com. (CMS estimated $4.7B in RADV extrapolation recoveries 2023–2032, per CMS impact analysis.)
10. National Law Review (Epstein Becker Green). “CMS Doubles Down on Medicare Advantage Recoupment.” May 2025. natlawreview.com. (CMS: intent to audit ~550 eligible MA contracts annually; workforce expansion from 40 to ~2,000 coders.)
11. Groom Law Group. “Court Rules That CMS Cannot Extrapolate Medicare Advantage Risk Adjustment Audit Results.” October 8, 2025. groom.com. (Federal district court vacated RADV extrapolation provisions, September 25, 2025; HHS appealed November 21, 2025.)
12. Wolters Kluwer. “Medicare Advantage Plans Face Risks Under CMS RADV Audit Changes.” June 2025. wolterskluwer.com. (OIG audit: $480K sample extrapolated to $27M.)
13. eCFR. 42 CFR § 438.8 — Medical Loss Ratio Standards. ecfr.gov.
14. Healthcare Dive. “Centene Swings to Loss But Predicts Stabilization in 2026.” February 6, 2026. healthcaredive.com. (Centene Q4 2025 Medicaid MLR: 93.0%.)
15. 42 CFR § 455.23 — Suspension of Payments in Cases of Fraud.